Leronlimab(Leronlimab) - 药物靶点：CCR5_在研适应症：转移性结直肠癌，微卫星稳定型结直肠癌，不能切除的大肠癌_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Leronlimab (USAN/INN)、Leronlimab-PRO 140、leronlimab-PRO140

+ [6]

靶点

CCR5

作用方式

拮抗剂

作用机制

CCR5拮抗剂(C-C趋化因子受体5型拮抗剂)

治疗领域

肿瘤消化系统疾病神经系统疾病+ [1]

在研适应症

转移性结直肠癌微卫星稳定型结直肠癌不能切除的大肠癌+ [2]

非在研适应症

急性移植物抗宿主病急性髓性白血病新型冠状病毒感染+ [6]

原研机构

CytoDyn, Inc.

在研机构

CytoDyn, Inc.

非在研机构-

权益机构

The American Foundation For AIDS Research, Inc.

BIOMM SA

MacLeods Pharmaceuticals Ltd.

+ [8]

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评快速通道 (美国)、孤儿药 (美国)、紧急使用授权 (加拿大)

登录后查看时间轴

结构/序列

Sequence Code 651154043H

来源: *****

Sequence Code 651154044L

来源: *****

关联

26

项与 Leronlimab 相关的临床试验

NCT06699836

/ Recruiting临床2期

A Phase Two Study Evaluating Two Doses of Leronlimab (Pro 140) In Combination With Trifluridine + Tipiracil (TAS-102) + Bevacizumab in Participants With CCR5+, Microsatellite Stable (MSS), Relapsed Refractory Metastatic Colorectal Cancer (mCRC)

This is an open label, randomized, two arm, multi-center study to explore the effect of leronlimab on the overall response rate/ overall survival and safety and tolerability when used in combination with trifluridine and tipiracil + bevacizumab in patients with CCR5+, MSS, mCRC who have progressed on prior treatment before participating in the study. The main questions this study aims to answer are:
1. Can leronlimab, in combination with standard of care therapies trifluridine and tipiracil+ bevacizumab, increase the objective response rate in persons with CCR5+, MSS, mCRC who have progressed on prior treatment before participating in the study.
2. Is leronlimab safe and well tolerated in these subjects when used in combination with standard of care therapies trifluridine and tipiracil+ bevacizumab.

开始日期2025-06-16

申办/合作机构

CytoDyn, Inc.

[+1]

NCT05730673

/ Withdrawn临床2期

A Phase II Study of Leronlimab (PRO 140) in Combination With Regorafenib in Patients With CCR5+, Microsatellite Stable (MSS), Metastatic Colorectal Cancer (mCRC)

This is aPhase II Study of Leronlimab (PRO 140) in combination with Regorafenib in Patients with CCR5+, Microsatellite Stable (MSS), Metastatic Colorectal Cancer (mCRC)

开始日期2022-09-20

申办/合作机构

CytoDyn, Inc.

[+1]

NCT04901689

/ Suspended临床3期IIT

A Phase 3, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Leronlimab in Combination With Standard of Care for Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation

Leronlimab (PRO 140) is a humanized IgG4,k monoclonal antibody (mAb) that recognizes the C-C chemokine receptor type 5 (CCR5). Disruption of the C-C chemokine ligand 5 (CCL5)-CCR5 axis via leronlimab-mediated CCR5 blockade might prevent pulmonary trafficking of pro-inflammatory leukocytes and dampen pathogenic immune activation in coronavirus disease 2019 (COVID-19).
The purpose of the study is to assess the safety and efficacy of leronlimab plus standard of care in critically ill patients hospitalized with COVID-19 pneumonia who are requiring mechanical ventilation or extracorporeal oxigenation (ECMO).

开始日期2021-10-23

申办/合作机构

Hospital Israelita Albert Einstein

[+1]

100 项与 Leronlimab 相关的临床结果

登录后查看更多信息

100 项与 Leronlimab 相关的转化医学

登录后查看更多信息

100 项与 Leronlimab 相关的专利（医药）

登录后查看更多信息

61

项与 Leronlimab 相关的文献（医药）

2025-09-01·JOURNAL OF MOLECULAR MODELING

Quantum chemical calculations based on 4,5-di(1,2,4-oxadiazol-3-yl)-2H-1,2,3-triazole and 3,3′ -(2H-1,2,3-triazole-4,5-diyl)-bis(1,2,4-oxadiazol-5(4H)-one) derivatives: a DFT study

Article

作者: Zhang, Peng ; Ma, Peng ; Chu, YuQin ; Ma, CongMing ; Zhu, Yang ; Jiang, Wen

CONTEXT:

1,2,3-Triazole has excellent thermal stability, and both 1,2,3-triazole and 1,2,4-oxazolium are good in structural modifiability. This study employed density functional theory (DFT) to design 24 target compounds (designated PA-1 to PA-24) based on the characteristics of these two heterocyclic systems. Using 4,5-diallyl-2H-1,2,3-triazole-3,3'-(2H-1,2,3-triazole-4,5-diyl)-bis(1,2,4-oxadiazol-5(4H)-one) as the parent compound (labeled A1), we introduced different energetic substituents at the C3 position of the oxadiazole ring and the N2 position of the triazole ring. Alternatively, using 3,3'-(2H-1,2,3-triazole-4,5-diyl)-bis(1,2,4-oxadiazol-5(4H)-one) as the parent compound (labeled A2), we introduced different energetic substituents at the N2 position of the triazole ring. The selection process considered both macroscopic properties (heat of formation and detonation performance) and microscopic factors including frontier molecular orbitals, energy gaps, weak interactions, surface electrostatic potential, and bond parameters. This approach aimed to identify energetic materials with both detonation performance and safety characteristics while investigating how introducing different substituents at these two positions affects detonation performance and safety. The research results indicate the following: First, introducing an azide group at the C3 position of the oxadiazole in A1 more effectively enhances the compound's heat of formation. PA-13 (△H_f,sold = 972.97 kJ/mol), PA-14 (△H_f,sold = 1023.62 kJ/mol), and PA-15 (△H_f,sold = 1069.24 kJ/mol), which all contain azide groups, rank among the top three in heat of formation among the 24 compounds. Second, PA-6 (D = 9.31 km/s, P = 39.93 GPa, Q = 7.39 kJ/g) exhibits the best detonation performance: its detonation pressure exceeds those of RDX (G = 36GPa), its detonation velocity and detonation heat surpass that of HMX (D = 9 km/s, Q = 6.4 kJ/g), and it achieves the ideal state of zero oxygen balance, resulting in the highest energy utilization efficiency. Third, PA-19 showed the least impact sensitivity and showed the potential of an insensitive explosive. Fourth, hydrogen bonds are common in the molecular structure of PA-8 ~ PA-12 derivatives of A2, which may contribute to the stability of the molecules. Fifth, trinitromethyl and dinitromethyl groups are more prone to fragmentation. The substituents introduced at the C3 position of the oxadiazole have almost no effect on the ring length of the oxadiazole, but introducing trinitromethyl at the N2 position of the triazole causes the triazole ring structure to expand, resulting in an increased ring length.

METHOD:

All calculations in this paper are based on density functional theory and were performed using the Gaussian16 software. Initially, the structures of PA-1 to PA-24 were optimized at the B3LYP-D3/6-311G** level. Subsequently, single-point energy calculations were conducted at the M06-2X-D3/def2-TZVPP level to determine the formation enthalpy, detonation velocity, and detonation pressure of the compounds. The Multiwfn and VMD programs were used to plot the energy gap diagrams, isosurface maps, scatter plots, and surface electrostatic potential maps for PA-1 to PA-24.

2025-06-01·JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Leronlimab Treatment for Multidrug-Resistant HIV-1 (OPTIMIZE): A Randomized, Double-Blind, Placebo-Controlled Trial

Article

作者: Hansen, Scott G. ; Dejesus, Edwin ; Sanchez, William E. ; Gathe, Joseph C. ; Meidling, Joseph ; Lalezari, Jacob P. ; Sacha, Jonah B. ; Krishen, Alok ; Ramgopal, Moti N. ; Rolle, Charlotte-Paige ; Yang, Otto O.

Background::

Leronlimab is a humanized κ-IgG4 monoclonal antibody that blocks C–C chemokine receptor type 5. We investigated leronlimab as a treatment option for people living with multidrug-resistant HIV-1.

Setting and Methods::

In a phase 2b/3, multicenter, randomized, double-blind, placebo-controlled study conducted in 21 hospital centers in the United States, treatment-experienced people living with HIV with documented drug resistance were randomly assigned once weekly leronlimab (350 mg subcutaneously) or matching placebo for 1 week overlapping existing failing antiretroviral therapy, followed by a 24-week single-arm extension with weekly leronlimab combined with a new optimized background treatment. The primary end point was achieving ≥0.5 log10 reduction in plasma HIV-1 RNA from baseline at the end of the 1-week double-blinded treatment period.

Results::

Fifty-two participants were enrolled (25 leronlimab and 27 placebo). After the 1-week randomized phase, by the intent-to-treat analysis, 64.0% (16/25) receiving leronlimab achieved ≥0.5 log10 reduction in plasma HIV-1 RNA versus 23.1% (6/26) receiving placebo (P = 0.0032), whereas by per protocol analysis, 72.7% (16/22) receiving leronlimab achieved ≥0.5 log10 reduction in plasma HIV-1 RNA versus 24.0% (6/25) receiving placebo (P = 0.0008). Leronlimab was generally well tolerated with no drug-related serious adverse events reported. Overall, 175 adverse events were reported by 34/52 participants, with 120 (68.6%) adverse events categorized as mild.

Conclusions::

Leronlimab resulted in significantly reduced plasma HIV-1 within 1 week after addition to failing antiretroviral therapy. After 24 weeks combined with an optimized background treatment, most participants had plasma HIV-1 RNA levels <50 copies per milliliter plasma, suggesting utility of leronlimab as a component of salvage therapy.

2025-04-15·JOURNAL OF VIROLOGY

Addition of a short HIV-1 fusion-inhibitory peptide to PRO 140 antibody dramatically increases its antiviral breadth and potency

Article

作者: Gao, Yue ; Zhu, Yuanmei ; Chen, Yue ; Su, Bin ; Gong, Yani ; Chong, Huihui ; Li, Li ; Yan, Hongxia ; He, Yuxian

ABSTRACT:

PRO 140, a humanized anti-HIV monoclonal antibody targeting the cell coreceptor CCR5, is currently under clinical trials, but it only affects CCR5-tropic viruses. In this study, we have engineered two tandem fusion proteins (2P23-PRO140SC and 2P23-PRO140-Fc) with bifunctional activity by adding short fusion-inhibitory peptide 2P23 to the single-chain fragment variable (scFv) of PRO 140 (PRO140SC) with or without the Fc domain of human IgG4. We first demonstrated that 2P23-PRO140SC and 2P23-PRO140-Fc could efficiently bind to the cell membranes through CCR5 anchoring, which did not affect the expression level of CCR5 on the cell surface. We then verified that the addition of 2P23 peptide to PRO140SC enabled a very potent activity against CXCR4-tropic HIV-1 isolates. As expected, the bispecific fusion proteins exhibited highly potent activities in inhibiting divergent HIV-1 subtypes and viral mutants that were resistant to the fusion inhibitors 2P23 and T20, and they displayed relatively low in vitro cytotoxicity. Furthermore, both the fusion proteins had robust in vivo anti-HIV activities in rats, with 2P23-PRO140-Fc much better than 2P23-PRO140SC. In conclusion, our studies have provided bispecific HIV-1 inhibitors that overcome the drawbacks of PRO 140 antibody and offered novel tools for studying the mechanisms of HIV-1 infection.

IMPORTANCE:

Given that HIV-1 evolves with high variability and drug resistance, the development of novel antivirals is important. CCR5-directed antibody PRO 140 is currently under clinical trials, but it only inhibits CCR5-tropic HIV-1 isolates. The designed fusion proteins by adding a minimum fusion-inhibitory peptide to PRO 140 enable dramatically increased activities in inhibiting both CCR5-tropic and CXCR4-tropic viruses, thus offering novel antiviral agents with a bispecific functionality that can overcome the drawbacks of PRO 140 antibody.

170

项与 Leronlimab 相关的新闻（医药）

2026-01-27

·BioSpace

CytoDyn’s Former CEO Gets Jail Time, $5.3M+ Fine for Securities Fraud

iStock, serggn Nader Pourhassan, who led CytoDyn for nearly 10 years, was convicted in December 2024 of misleading investors regarding the biotech’s investigational COVID-19 and HIV drug, which artificially inflated its share price. The Department of Justice has sentenced Nader Pourhassan, the former CEO of CytoDyn, to 30 months in prison after he was convicted of securities fraud and insider trading. Pourhassan intentionally made misleading claims about leronlimab, an experimental antibody that CytoDyn was developing for HIV and COVID-19, according to a Department of Justice release on Monday. The ex-CEO’s scheme ran from 2018 to 2021 and served to “artificially inflate” CytoDyn’s stock price and attract new investors, the DOJ stated. Pourhassan then sold 4.8 million company shares that he owned, earning $4.4 million in the process. The former top executive “exploited a deadly public health crisis to intentionally deceive investors and the public out of millions—all so that he could enrich himself,” U.S. Attorney Kelly Hayes, for the District of Maryland, said in a statement. Aside from jail time, Pourhassan was also ordered by the court to pay more than $5.3 million in restitution and surrender over $4.4 million. Leronlimab, a humanized IgG4 monoclonal antibody, was initially being developed for HIV before CytoDyn decided to pivot and propose the therapy for COVID-19. In May 2021, however, the FDA publicly contradicted these plans, noting that “the data currently available do not support the clinical benefit of leronlimab for the treatment of COVID-19.” The rebuke came after leronlimab failed a Phase III study in March 2021, unable to significantly boost survival in hospitalized COVID-19 patients versus placebo. Pourhassan nevertheless dug into the data and put a positive spin on the outcomes. “We believe these results are the best results ever achieved for this population in a Phase 3 clinical trial,” he claimed at the time. Monday’s sentencing comes after a federal jury in Maryland in December 2024 found Pourhassan guilty of four counts of securities fraud, two counts of wire fraud and three counts of insider trading. Alongside Pourhassan, the jury also found guilty Kazem Kazempour, who at the time of Pourhassan’s scheme was CEO of Amarex Clinical Research, a third-party contract research organization that ran CytoDyn’s studies. Kazempour, according to the original complaint, collaborated with Pourhassan and earned more than $340,000. Kazempour was convicted of one count of securities fraud and one of wire fraud—though these have since been vacated , according to a press announcement from the law firm representing Kazempour last Thursday. He will face a new trial, according to the statement. Pourhassan became CytoDyn’s CEO in September 2012 and held that post until January 2022, when the company’s board of directors voted to let him go and search for another executive that could better lead the commercialization of leronlimab.

临床3期高管变更

2026-01-26

·EndPoints

Ex-CytoDyn CEO sentenced to 30 months for pump-and-dump scheme

CytoDyn’s former CEO Nader Pourhassan was sentenced Friday to 30 months in prison for misleading investors about the prospects of a potential drug and then selling his personal stock in the company at artificially inflated prices. Prior to Pourhassan’s firing in 2022, CytoDyn was known for its aggressive promotional campaigns to tout the unsubstantiated potential of its drug leronlimab for Covid-19, the Department of Justice said. Pourhassan appeared on webcasts and recorded videos to push the drug, even after the FDA rejected it as a treatment for HIV, its original indication, and the drug failed a pair of Covid-19 studies. The DOJ said Monday that between 2018 and 2021, Pourhassan intentionally misled investors about leronlimab’s prospects for approval. Pourhassan then sold his 4.8 million shares of CytoDyn stock and pocketed $4.4 million, the department said. Pourhassan was initially charged in 2022. In 2024, he was convicted at trial of four counts of securities fraud, two counts of wire fraud and three counts of insider trading. At sentencing, he was ordered to pay more than $5.3 million in restitution and to forfeit more than $4.4 million, the DOJ said.

高管变更专利侵权

2026-01-06

·中国生物器材网

从艾滋病毒到免疫疾病的新兴靶标：CCR5的结构、受体功能及应用

在人类与疾病斗争的漫长历史中，CCR5受体曾因艾滋病的出现而声名大噪——它曾是HIV入侵细胞的“关键钥匙”，也因此成为抗艾药物的重要靶点。然而，它的故事远不止于此。从基因编辑婴儿的伦理争议，到癌症免疫治疗的新希望，CCR5正在免疫与炎症疾病的广阔舞台上，展现其复杂而多面的生物学角色。一、CCR5受体结构 CC趋化因子受体5型（Chemokine receptor 5，CCR5）是一种主要表达于免疫细胞表面的G蛋白偶联受体。它能特异性结合趋化因子，从而在免疫监视和炎症反应中发挥核心作用，其配体包括CCL3、CCL4、CCL5、CCL7等。 CCR5受体由352个氨基酸残基组成，分子量约为40.6kDa，其结构包括胞外N末端、三个胞外环（EL1、EL2、EL3）、三个胞内环（IL1、IL2、IL3）、7个跨膜α螺旋和胞内C末端（如下图所示）。二、CCR5受体信号通路由CKLF1/CCR5、CCL5/CCR5等信号轴介导的炎症涉及MAPK、NF-κB、PI3K/Akt、mTOR、HIF-α及JAK-STAT多条关键信号通路。这些通路并非孤立运作，而是相互关联、协同作用，共同驱动炎症进程。 MAPK信号通路（见下图）：趋化因子 (如CCL3, CKLF1) → 结合并激活 CCR5 → ERK磷酸化 → 激活 RAS-ERK-MEK 通路，该通路是MAPK信号网络中的关键分支，这些级联反应共同驱动了CCR5介导的炎症过程。 NF-κB信号通路（见下图）：趋化因子 (如CKLF1, CCL5) → 结合并激活 CCR5 → 触发 NF-κB 释放与入核 → 启动炎症基因转录 PI3K/Akt/mTOR信号通路（见下图）： CCR5 被激活 → 磷酸化并激活 Akt → 同时解除对 mTOR 的抑制 → 协同驱动细胞生长、代谢等下游效应三、CCR5受体功能与相关疾病 CCR5是免疫细胞表面一种关键的“导航信号接收器”，其主要功能在于引导免疫细胞定向迁移至炎症或感染部位，并精准调控炎症反应的强度。与此同时，它也是HIV病毒入侵细胞所必需的主要共受体，其基因功能缺失（如CCR5-Δ32突变）可导致对HIV感染的天然耐受。基于这一双重角色，CCR5不仅成为抗艾滋病药物研发的经典靶点，其异常激活或表达也广泛参与多种疾病进程。因此，CCR5已成为连接感染、肿瘤、自身免疫及神经炎症等多个疾病领域的枢纽靶点，其药物研发也从单一的艾滋病治疗，拓展至癌症免疫联合治疗和炎症性疾病干预等广阔方向。 CCR5在中枢神经系统炎症疾病中的核心作用机制（如下图） CCR5是参与多种脑部疾病炎症过程的关键因子，其机制贯穿中风、阿尔茨海默病（AD）、帕金森病（PD）、癫痫、抑郁症和多发性硬化（MS）等疾病。针对其信号通路开发靶向疗法，有望为治疗上述神经系统疾病提供新的干预策略。 CCR5在非神经器官炎症疾病中的作用机制（如下图） CCR5是心脏、肝脏、肠道等多个器官炎症反应的关键共同介导因子。针对CCR5通路的靶向干预，有望为治疗心肌损伤、肝炎和IBD等疾病提供新的治疗策略。四、CCR5受体相关药物研发针对CCR5受体的药物研发，已经从单一的艾滋病治疗领域，扩展至癌症、肝脏及神经系统炎症等多个重要疾病方向。马拉韦罗 (Maraviroc)：它是首个也是目前唯一获批临床使用的CCR5靶向药。作为一种小分子拮抗剂，它通过“变形”CCR5受体来阻止HIV-1病毒侵入细胞。它专用于治疗仅感染“R5嗜性”HIV病毒的患者，是CCR5靶向疗法的基石。 Leronlimab (PRO 140)：这是一种人源化单克隆抗体，与受体结合力强、作用持久。它不仅被用于长效治疗HIV感染的临床试验，更在癌症治疗领域展现出巨大潜力。例如，它正被研究用于三阴性乳腺癌和结直肠癌，旨在通过阻断CCR5来改善肿瘤微环境、抑制转移。塞尼韦罗 (Cenicriviroc)：作为一种口服小分子双拮抗剂，它能同时抑制CCR2和CCR5这两个密切相关的受体。研发重点并非艾滋病，而是非酒精性脂肪性肝炎 (NASH) 等炎症纤维化疾病，旨在从源头抑制驱动疾病进展的炎症信号。格宁生物相关实验关于我们上海格宁生物科技有限公司（ScreeNingBio）成立于2020年，位于上海市浦江高科技园，专业提供生物医药研发外包服务，服务内容涵盖小分子和大分子药物研发早期阶段的多个方面，包括功能细胞株、药物筛选、高通量筛选、选择性和安全性评价、体外模型开发与验证、药物作用机理等。格宁生物不断自主开发新的药物靶点细胞株（如GPCR, Ion Channel）及各种药物筛选模型，全力打造筛选模型丰富、实验操作严谨、结果可信的药物筛选平台，为国内外医药企业提供优质高效的技术服务。联系我们电话：400-863-1023 邮箱：info@screeningbio.com 地址：上海市闵行区联航路1188号24号楼4层参考文献 Lin Y, Liu S, Sun Y, Chen C, Yang S, Pei G, Lin M, Yu J, Liu X, Wang H, Long J, Yan Q, Liang J, Yao J, Yi F, Meng L, Tan Y, Chen N, Yang Y, Ai Q. CCR5 and inflammatory storm. Ageing Res Rev. 2024 Apr;96:102286. doi: 10.1016/j.arr.2024.102286. Epub 2024 Mar 30. PMID: 38561044. Faivre N, Verollet C, Dumas F. The chemokine receptor CCR5: multi-faceted hook for HIV-1. Retrovirology. 2024 Jan 23;21(1):2. doi: 10.1186/s12977-024-00634-1. PMID: 38263120; PMCID: PMC10807162. Oppermann M. Chemokine receptor CCR5: insights into structure, function, and regulation. Cell Signal. 2004 Nov;16(11):1201-10. doi: 10.1016/j.cellsig.2004.04.007. PMID: 15337520.

100 项与 Leronlimab 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11399	Leronlimab	-	DB05941

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
HIV感染	申请上市	美国	CytoDyn, Inc.	2021-11-01
新型冠状病毒感染	临床3期	美国	CytoDyn, Inc.	2020-08-05
不能切除的大肠癌	临床2期	美国	CytoDyn, Inc.	2025-06-16
转移性结直肠癌	临床2期	-	CytoDyn, Inc.	2022-09-20
转移性微卫星稳定结直肠癌	临床2期	-	CytoDyn, Inc.	2022-09-20
微卫星稳定型结直肠癌	临床2期	-	CytoDyn, Inc.	2022-09-20
新冠肺炎后遗症	临床2期	美国	CytoDyn, Inc.	2021-03-01
代谢功能障碍相关脂肪性肝炎	临床2期	美国	CytoDyn, Inc.	2020-12-01
转移性实体瘤	临床2期	美国	CytoDyn, Inc.	2020-05-01
三阴性乳腺癌	临床2期	美国	CytoDyn, Inc.	2019-04-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04504942 (Phase 2 single-arm basket study, CTgov)	临床2期	转移性实体瘤 \| 实体瘤	16	Leronlimab	構鹹餘淵艱醖願壓選膚 = 齋選鏇製膚顧願醖糧壓網鑰簾獵醖膚淵簾構範 (鏇鹽鹽製鑰鏇網獵糧憲, 醖願鬱顧窪積壓願構糧 ~ 遞廠範繭鑰膚簾範襯糧) 更多	-	2026-01-23
NCT03838367 (SABCS2025)	临床1/2期	三阴性乳腺癌 PD-L1 \| PD-1 \| CCR5	28	Leronlimab ± immune checkpoint inhibitors (ICI) + various chemotherapies	夢鏇廠鏇觸構憲鑰製襯(鏇築憲淵襯構築築獵範) = 鹽醖壓網淵廠簾築鹹製齋積遞觸選積壓窪觸繭 (廠襯願壓構鑰遞鏇願鹹 ) 更多	积极	2025-12-12
NCT02990858 (CTgov)	临床2/3期	HIV感染	43	PRO 140 (leronlimab) (PRO 140)	顧醖鏇廠襯鏇憲製鬱鹽(夢構糧構顧艱齋鹽遞鏇) = 繭憲繭醖餘衊繭繭醖膚艱積鬱獵蓋構襯獵網鹹 (繭窪醖衊範觸艱淵獵鑰, 1.11) 更多	-	2025-11-12
NCT02990858 (CTgov)	临床2/3期	HIV感染	43	PRO 140 (leronlimab) (PRO 140 350 mg)	糧膚積積衊壓網願餘夢(觸選蓋艱觸鹽醖夢獵衊) = 餘製襯簾鑰齋築網觸簾築餘願簾蓋繭衊範鏇獵 (糧齋築餘齋壓觸醖鏇糧, 餘製鹽淵廠簾醖繭窪鑰 ~ 獵夢膚艱壓鏇觸鏇網網) 更多	-	2025-11-12
NCT05271370 (CTgov)	临床2/3期	HIV感染	56	PRO 140 350 (PRO 140 350 mg)	夢遞網製壓壓衊製鹽選 = 壓選範繭窪窪廠蓋構壓壓網鏇壓鏇蓋窪艱膚範 (壓醖範淵願醖簾簾醖範, 網積鏇網醖淵膚繭願鬱 ~ 膚鏇繭鑰製築簾餘膚艱) 更多	-	2025-10-30
NCT05271370 (CTgov)	临床2/3期	HIV感染	56	PRO 140 525 (PRO 140 525 mg)	夢遞網製壓壓衊製鹽選 = 淵廠鑰顧醖遞鑰鏇鹹遞壓網鏇壓鏇蓋窪艱膚範 (壓醖範淵願醖簾簾醖範, 襯蓋鹹齋積衊淵顧壓鬱 ~ 築廠襯膚鬱壓蓋願齋遞) 更多	-	2025-10-30
NCT02355184 (CTgov)	临床2期	HIV感染	20	PRO 140	鹹壓蓋網築鑰觸餘窪衊(遞構獵壓觸餘淵願簾鹽) = 簾顧淵糧鏇鏇鏇積鹽鏇糧蓋醖選鏇襯壓築選顧 (範築網鏇願顧蓋積衊衊, 225.6) 更多	-	2025-10-07
NCT03902522 (CTgov)	临床2/3期	HIV感染	6	PRO 140	衊廠鏇蓋簾憲網膚選製 = 艱積憲廠網遞醖築鹽衊膚繭蓋蓋顧艱襯鬱鏇鏇 (獵鏇繭構構範襯廠顧鏇, 淵壓齋鬱憲鹹窪網窪艱 ~ 觸衊淵糧鏇構鏇艱鬱壓) 更多	-	2025-09-16
NCT03838367 (CTgov)	临床1/2期	三阴性乳腺癌	10	AUC 5 Carboplatin+leronlimab (Phase II- MTD to be Established for the Combination Treatment)	艱顧蓋蓋窪鹹憲鬱觸憲(獵製製壓廠衊繭鹹積衊) = 醖廠築繭築獵淵遞願醖觸積製蓋遞遞襯壓築選 (繭網網憲遞艱製膚積糧, 簾範鹽鬱齋鬱夢鏇鏇鏇 ~ 齋襯獵鏇壓窪選鹹膚範) 更多	-	2025-09-09
NCT03838367 (CTgov)	临床1/2期	三阴性乳腺癌	10	AUC 5 Carboplatin+350 mg leronlimab (Phase I-Cohort A: 350 mg PRO 140 SC Weekly + AUC 5 Carboplatin)	鹽壓醖淵構艱壓憲顧願 = 鹽積鏇糧積憲構壓壓醖廠齋鹽製積簾構積選網 (艱齋憲願夢餘壓觸壓觸, 積齋襯窪鑰廠觸顧餘鹽 ~ 鹹繭鏇艱鬱膚餘鹹鹹糧) 更多	-	2025-09-09
NCT04347239 (CTgov)	临床2期	新型冠状病毒感染	484	Placebo (Placebo)	網衊製鏇遞襯鏇鑰餘遞 = 網簾淵蓋鬱窪遞選繭構範醖鹽鹽襯構餘顧繭憲 (夢鏇糧願範網襯獵製壓, 夢鏇廠衊構積鏇鏇糧構 ~ 網廠衊淵蓋遞繭醖壓築) 更多	-	2025-08-27
NCT04347239 (CTgov)	临床2期	新型冠状病毒感染	484	Leronlimab (700mg) (700mg Leronlimab)	網衊製鏇遞襯鏇鑰餘遞 = 願顧築積構淵鏇齋鑰鏇範醖鹽鹽襯構餘顧繭憲 (夢鏇糧願範網襯獵製壓, 衊襯蓋夢觸鬱遞遞製鹹 ~ 遞繭鑰憲顧糧淵鹹繭獵) 更多	-	2025-08-27
NCT04504942 (Phase 2 single-arm basket study, ESMO_GI2025)	临床2期	转移性结直肠癌 CCR5-positive tumors	5	Leronlimab	窪醖鏇繭鹹築鹹網鹹艱(簾壓衊夢築淵獵選餘選) = Two patients had grade 1 AEs that were deemed treatment related (infusion-related reaction and nausea) 襯鏇鏇鏇齋顧構餘構選 (夢顧憲衊鏇淵構糧製襯 )	积极	2025-07-03
NCT03838367 \| NCT04504942 \| NCT04313075 (ESMO_BC2025)	N/A	转移性三阴性乳腺癌 CCR5	28	Leronlimab	顧構選築糧製夢獵膚夢(遞鏇壓積鹽簾顧艱窪範) = No DLTs were observed in NCT03838367 after dose escalation to 700 mg (n=10) 壓壓醖顧繭遞窪鹽築簾 (鑰願膚構壓醖選選範網 ) 更多	积极	2025-05-14